A Phase 1, Open-Label, Dose-Finding Study of BMS-986453, Dual Targeting BCMAxGPRC5D Chimeric Antigen Receptor T Cells, in Participants With Relapsed and/or Refractory Multiple Myeloma

Disease Name: 
Multiple Myeloma (MM)
Study Status: 
Date: 
July 19, 2024